US20040242466A1 - Use of a glycoprotein for the treatment and re-epithelialisation of wounds - Google Patents
Use of a glycoprotein for the treatment and re-epithelialisation of wounds Download PDFInfo
- Publication number
- US20040242466A1 US20040242466A1 US10/480,538 US48053804A US2004242466A1 US 20040242466 A1 US20040242466 A1 US 20040242466A1 US 48053804 A US48053804 A US 48053804A US 2004242466 A1 US2004242466 A1 US 2004242466A1
- Authority
- US
- United States
- Prior art keywords
- glycoprotein
- wounds
- antarticine
- concentration
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q3/00—Manicure or pedicure preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
Abstract
Description
- The present invention relates to the use of a glycoprotein known as Antarticine-NF3 for preparing pharmaceutical, veterinarian and cosmetic compositions for treatment and re-epithelialization of wounds.
- Antarticine-NF3 is a glycoprotein produced byPseudoalteromonas antartica, a Gram-negative bacteria isolated from the Antarctic Ocean. This aerobic heterotropic bacterium has a single polar flagellum and produces a hexapolymeric glycoprotein (Antarticine-NF3) composed of 14% carbohydrate and 86% protein that completely surround it. Pseudoalteromonas antartica is perfectly adapted to the low temperatures of the Antarctic environment and withstands high salt concentrations.
- Antarticine-NF3 in solution forms regular aggregates by self-assembly. A gradual increase in the concentration of a solution of this glycoprotein causes a gradual reduction of the surface tension of the solution. In addition, Antarticine-NF3 is known for its great affinity to phosphatidylcholine liposome, coating them and protecting them from the permeabilisation effect of surfactants such as SDS, as described in WO98/42731. In addition, Antarticine-NF3 is known for inducing nucleation of ice and preventing the growth of large hexagonal ice crystals. These data suggest that Antarticine-NF3 is responsible for the adaptation ofPseudoalteromonas antartica to the environmental conditions of its Antarctic habitat.
- Furthermore, keratinocytes are a type of cell found in the epidermis, forming its deepest layer. Keratinocytes generate the outer skin layer (corneal stratum) by multiplication and modification of their structure until forming the layer of mature, keratinocytised cells on the surface of the skin. The speed of healing of wounds is influenced, among other factors, by the rate of proliferation and migration of keratinocytes. Any factor that enhances one of these processes will favour the healing and scarring process for wounds.
- As a result of our investigations we have found that, surprisingly, the soluble glycoprotein fromPseudoalteromonas antartica known as Antarticine-NF3, which consists of 14% carbohydrates and 86% protein, selectively improves the adhesion of human dermal fibroblasts and promotes the cellular growth of human epidermal keratinocytes. Thus, Antarticine-NF3 has surprisingly revealed itself as a good agent for improving scar formation in wounds.
- Thus, the object of the present invention is the use of Antarticine-NF3 in solutions or acceptable galenical formulations for use in the treatment and re-epithelialization of wounds in the pharmaceutical and veterinary fields, as well as for cosmetic regeneration treatments. The concentrations used of Antarticine-NF3 are between 100 mg/l and 1 fg/ml, and more specifically between 10 mg/ml and 0.1 ng/ml.
- As a complement of the description being made and in order to aid a better understanding of the characteristics of the invention, a few examples are provided below for purposes of illustration only and in a non-limiting sense. This invention should not be considered as limited by the realizations described.
- Experiments were carried out with the WST-1 test, which measures the activity of mitochondrial dehydrogenases in a non-radioactive calorimeter test using formazan salts. Different concentrations of glycoprotein were tested (between 1 mg/ml and 0.01 μg/ml). NaCl 0.01M was used as a negative control and SDS 0.02% was used as a positive control.
- The results obtained are shown in the following table:
Concentration Result tested on HDF Result on HEK Control 0.46 0.92 Negative control (NaCl) 0.01 M 0.43 0.7 Positive control (SDS) 0.02% 0.17 0.2 1 fg — 0.78 0.1 pg — 0.92 0.0 ng1 0.44 0.92 1 ng 0.43 1.02 0.1 μg 0.41 0.97 10 μg 0.42 0.8 1 mg 0.44 0.81 - As can be seen in the above table, the cytotoxicity tests revealed that Antarticine-NF3 does not show toxicity in human epidermal keratinocytes (HEK), nor in human dermal fibroblasts (HDF).
- Cellular adhesion tests in vitro revealed that Antarticine-NF3 has a specific effect on the adhesion of HDF. HDF cells showed a significant growth in cellular adhesion when growing on substrates coated with 1 mg/ml of Antarticine-NF3 after 2 and 5 hours of culture.
- The results obtained for HDF are shown in the following table:
Concentration tested Time 2 hours Time 5 hours Control 0.1 0.13 Glycoprotein 0.001 mg/ml 0.11 0.24 1 mg/ml 0.24 0.28 - The results obtained for HEK are shown in the following table:
Concentration tested Time 2 hours Time 5 hours Control 0.09 0.15 Glycoprotein 0.001 mg/ml 0.11 0.17 1 mg/ml 0.15 0.19 - As may be seen, in similar culture conditions the effect seen on HEK is not statistically significant.
- Experiments on in vitro cell growth conducted with the crystal violet elution method revealed that Antarticine-NF3 at different concentrations, in the presence or absence of a minimal amount of foetal cow serum (2% FCS) stimulates the growth of HEK cells, as shown in the following table:
Concentration Time 0 Time 24 Time 48 tested hours hours hours Control 0.2 0.16 0.58 Glycoprotein 10 μg/mL 0.15 0.78 0.1 μg/mL 0.16 0.77 0.001 μg/mL 0.18 0.77 - While similar experiments conducted with HDF cells did not show relevant results, as shown on the following table:
Concentration Time 0 Time 24 Time 48 tested hours hours hours Control 0.21 0.16 0.25 Glycoprotein 10 μg/mL 0.175 0.26 0.1 μg/mL 0.17 0.248 0.001 μg/mL 0.175 0.249 - Experiments for regeneration of wounds in vitro were conducted in cultures of differentiated HEK cells, in the presence and absence of FCS. The duration of the tests was seven days.
- Concentrations of Antarticine-NF3 above 0.1 ng/ml showed a positive effect on wound regeneration when compared to control cultures; this effect of Antarticine-NF3 on wound regeneration in vitro can be seen in FIG. 1 for a concentration of 0.1 μg/mL.
Claims (9)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ESP200101383 | 2001-06-14 | ||
ES200101383A ES2181592B1 (en) | 2001-06-14 | 2001-06-14 | USE OF GLICOPROTEIN FOR THE TREATMENT AND RE-EPITHELIZATION OF WOUNDS |
PCT/ES2002/000281 WO2002102406A1 (en) | 2001-06-14 | 2002-06-07 | Use of glycoprotein for the treatment and re-epithelialisation of wounds |
Publications (2)
Publication Number | Publication Date |
---|---|
US20040242466A1 true US20040242466A1 (en) | 2004-12-02 |
US7022668B2 US7022668B2 (en) | 2006-04-04 |
Family
ID=8498066
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/480,538 Expired - Lifetime US7022668B2 (en) | 2001-06-14 | 2002-06-07 | Use of a glycoprotein for the treatment and re-epithelialisation of wounds |
Country Status (12)
Country | Link |
---|---|
US (1) | US7022668B2 (en) |
EP (1) | EP1402898B1 (en) |
JP (1) | JP4252444B2 (en) |
KR (1) | KR20040030675A (en) |
AT (1) | ATE285787T1 (en) |
BR (1) | BRPI0210428B8 (en) |
CA (1) | CA2449910C (en) |
DE (1) | DE60202474T2 (en) |
ES (2) | ES2181592B1 (en) |
MX (1) | MXPA03011622A (en) |
PT (1) | PT1402898E (en) |
WO (1) | WO2002102406A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101126314B1 (en) | 2007-11-15 | 2012-03-23 | 한국해양연구원 | Novel Cryoprotective Exopolysaccharide |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100784486B1 (en) * | 2007-01-08 | 2007-12-11 | 주식회사 에스티씨나라 | Cosmetic compositions for skin-tightening and method of skin-tightening using the same |
ES2336995B1 (en) * | 2008-10-13 | 2011-02-09 | Lipotec, S.A. | COSMETIC OR DERMOPHARMACEUTICAL COMPOSITION FOR SKIN CARE, HAIR LEATHER AND NAILS. |
ES2390033B1 (en) * | 2010-11-30 | 2013-10-31 | Lipotec S.A. | EXOPOLISACÁRIDO FOR THE TREATMENT AND / OR CARE OF SKIN, MUCOSAS, HAIR AND / OR NAILS. |
WO2013121002A1 (en) | 2012-02-16 | 2013-08-22 | Arquebio, S. L. | Microorganism-free extract from hypersaline aqueous environments and process for its preparation |
WO2015063613A2 (en) | 2013-11-01 | 2015-05-07 | Spherium Biomed S.L. | Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents |
WO2016066857A1 (en) * | 2014-10-31 | 2016-05-06 | Lipotec, S.A.U. | Cosmetic and/or pharmaceutical composition containing a bacterial extracellular product from pseudoalteromonas antarctica, and use thereof |
EP3165233B1 (en) | 2015-08-28 | 2021-08-18 | Latvijas Universitate | Biomaterial for treatment of acute and chronic skin wounds |
KR102311724B1 (en) | 2017-09-15 | 2021-10-13 | (주)아모레퍼시픽 | Composition for whitening of skin comprising culture or its extract of pseudoalteromonas peptidolytica |
KR102395984B1 (en) | 2017-09-27 | 2022-05-11 | (주)아모레퍼시픽 | Composition for whitening of skin comprising culture or its extract of pseudoalteromonas carrageenovora |
EP3790568A1 (en) | 2018-05-08 | 2021-03-17 | Gat Biosciences, S.L. | Imac-enriched microalgal culture supernatant and uses thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2126516B1 (en) * | 1997-03-26 | 1999-12-01 | Univ Barcelona | GLYCOPROTEIN FOR PROTECTION OF LIPOSOMES. |
-
2001
- 2001-06-14 ES ES200101383A patent/ES2181592B1/en not_active Expired - Fee Related
-
2002
- 2002-06-07 AT AT02738185T patent/ATE285787T1/en active
- 2002-06-07 DE DE60202474T patent/DE60202474T2/en not_active Expired - Lifetime
- 2002-06-07 KR KR10-2003-7016338A patent/KR20040030675A/en not_active Application Discontinuation
- 2002-06-07 JP JP2003504992A patent/JP4252444B2/en not_active Expired - Lifetime
- 2002-06-07 EP EP02738185A patent/EP1402898B1/en not_active Expired - Lifetime
- 2002-06-07 ES ES02738185T patent/ES2236525T3/en not_active Expired - Lifetime
- 2002-06-07 US US10/480,538 patent/US7022668B2/en not_active Expired - Lifetime
- 2002-06-07 PT PT02738185T patent/PT1402898E/en unknown
- 2002-06-07 MX MXPA03011622A patent/MXPA03011622A/en active IP Right Grant
- 2002-06-07 BR BRPI0210428-8 patent/BRPI0210428B8/en not_active IP Right Cessation
- 2002-06-07 WO PCT/ES2002/000281 patent/WO2002102406A1/en active IP Right Grant
- 2002-06-07 CA CA2449910A patent/CA2449910C/en not_active Expired - Lifetime
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101126314B1 (en) | 2007-11-15 | 2012-03-23 | 한국해양연구원 | Novel Cryoprotective Exopolysaccharide |
Also Published As
Publication number | Publication date |
---|---|
EP1402898B1 (en) | 2004-12-29 |
EP1402898A1 (en) | 2004-03-31 |
DE60202474D1 (en) | 2005-02-03 |
ES2236525T3 (en) | 2005-07-16 |
JP4252444B2 (en) | 2009-04-08 |
BRPI0210428B8 (en) | 2021-05-25 |
ATE285787T1 (en) | 2005-01-15 |
BR0210428A (en) | 2004-08-17 |
KR20040030675A (en) | 2004-04-09 |
ES2181592B1 (en) | 2003-11-01 |
MXPA03011622A (en) | 2004-07-01 |
PT1402898E (en) | 2005-05-31 |
US7022668B2 (en) | 2006-04-04 |
ES2181592A1 (en) | 2003-02-16 |
BRPI0210428B1 (en) | 2018-04-17 |
DE60202474T2 (en) | 2005-12-29 |
WO2002102406A1 (en) | 2002-12-27 |
CA2449910A1 (en) | 2002-12-27 |
CA2449910C (en) | 2013-01-08 |
JP2004534076A (en) | 2004-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5591709A (en) | Compositions and methods for treating wounds | |
US5770582A (en) | Pharmaceutical compositions containing deoxyribonucleosides for wound healing | |
US4885163A (en) | Topical use of IGF-II for wound healing | |
US8183204B2 (en) | Methods and compositions for increasing skin remodeling | |
EP0650366B1 (en) | Compositions and methods for treating wounds | |
US6048886A (en) | Compositions and delivery systems for the topical treatment of psoriasis and other conditions of the skin | |
US7022668B2 (en) | Use of a glycoprotein for the treatment and re-epithelialisation of wounds | |
US7834055B2 (en) | Compositions and methods for the treatment of skin | |
WO1989006958A1 (en) | Topical l-carnitine composition | |
US6262020B1 (en) | Topical wound therapeutic compositions | |
CA2322199A1 (en) | Inorganic nitrite and organic acid in combination as topical antiviral composition | |
EP0447414B1 (en) | Use of minoxidil for wound healing | |
US20200016089A1 (en) | Composition and methods for tissue regeneration | |
WO2008035243A2 (en) | Composition for treatment of burns and wounds | |
EP0420862B1 (en) | Pharmaceutical composition containing deoxyribonucleosides for wound healing | |
CA2321829C (en) | Topical composition containing human epidermal growth factor | |
EP0470431A2 (en) | Use of fosfomycin pharmaceutically acceptable salts as a topical cicatrizer | |
US20120183630A1 (en) | Compositions and methods for stimulating wound healing | |
US6919320B1 (en) | Pharmaceutical compositions containing deoxyribonucleosides for wound healing | |
KR100231805B1 (en) | Topical formulations containing human epidermal growth factor | |
JPS63215631A (en) | Wound remedy | |
WO2002064178A1 (en) | Use of green tea extract for wound healing | |
GB2372210A (en) | Wound healing | |
WO2013187899A1 (en) | Compositions and methods for stimulating wound healing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: LIPOTEC S.A., SPAIN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PARENTE DUENA, ANTONIO;GARCES GARCES, JOSEP;GUINEA SANCHEZ, JESUS;AND OTHERS;REEL/FRAME:016665/0701;SIGNING DATES FROM 20031209 TO 20031210 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FEPP | Fee payment procedure |
Free format text: PAT HOLDER NO LONGER CLAIMS SMALL ENTITY STATUS, ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: STOL); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553) Year of fee payment: 12 |